clinical trial · NCT01840592
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Hepatocellular CarcinomaSorafenibDoxorubicin
brief summary
The purpose of this study is to find out what effects, good and/or bad, the combination of the drug sorafenib in combination with the drug doxorubicin might have on the growth and spread of liver cancer (HCC).
started
Apr 1, 2013
primary completion
Apr 1, 2027
completion
Apr 1, 2027
last updated
May 6, 2026
official title
Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol